Premium
The American society of clinical oncology position on genetic testing
Author(s) -
Garber Judy E.,
Offit Kenneth,
Olopade O. I. Funmi,
Fink Diane,
Barbasch Avi,
Barr Patricia,
Gleeson Robert K.,
Stage Barbara Le
Publication year - 1997
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19970801)80:3+<632::aid-cncr16>3.0.co;2-f
Subject(s) - medicine , clinical oncology , genetic testing , position paper , medical physics , oncology , family medicine , intensive care medicine , cancer , pathology
Judy E. Garber, M.D., M.P.H. (Co-Chair) I Kenneth Offit, M.D., M.P.H. (Co-Chair) n formulating a review of the position statement of the American Society of Clinical Oncology (ASCO), this panel of the American O. I. (Funmi) Olopade, M.D. (Co-Chair) Cancer Society (ACS) views this initiative as part of similar efforts by Diane Fink, M.D. (Rapporteur) a number of other professional, consumer, and policy-based organiAvi Barbasch, M.D.* zations. Summarized below are paraphrased highlights from the ASCO Patricia Barr, J.D.* statement, on which there is a broad consensus among most of the Robert K. Gleeson, M.D.* organizations that have issued statements in this area. Barbara Le Stage, M.H.P.* Key points of consensus regarding cancer genetic counseling and testing include emphasis on: